abstract: Gain of 20q11.21 is a chromosomal abnormality that is recurrently found in human pluripotent stem cells and cancers, strongly suggesting that this mutation confers a proliferative or survival advantage to these cells. In this work we studied three human embryonic stem cell (hESC) lines that acquired a gain of 20q11.21 during in vitro culture. The study of the mRNA gene expression levels of the loci located in the common region of duplication showed that HM13, ID1, BCL2L1, KIF3B and the immature form of the micro-RNA miR-1825 were up-regulated in mutant cells. ID1 and BCL2L1 were further studied as potential drivers of the phenotype of hESC with a 20q11.21 gain. We found no increase in the protein levels of ID1, nor the downstream effects expected from over-expression of this gene. On the other hand, hESC with a gain of 20q11.21 had on average a 3-fold increase of Bcl-xL (the anti-apoptotic isoform of BCL2L1) protein levels. The mutant hESC underwent 2-to 3-fold less apoptosis upon loss of cell-to-cell contact and were 2-fold more efficient in forming colonies from a single cell. The key role of BCL2L1 in this mutation was further confirmed by transgenic over-expression of BCL2L1 in the wild-type cells, leading to apoptosis-resistant cells, and BCL2L1-knock-down in the mutant hESC, resulting in a restoration of the wild-type phenotype. This resistance to apoptosis supposes a significant advantage for the mutant cells, explaining the high frequency of gains of 20q11.21 in human pluripotent stem cells.
Introduction
Since the introduction of high-resolution molecular cytogenetic methods for the screening for genetic changes in human embryonic stem cells (hESC), numerous laboratories worldwide have reported the gain of 20q11.21 as a recurrent mutation (Lefort et al., 2008; Spits et al., 2008; Wu et al., 2008; Elliott et al., 2010; Närvä et al., 2010; Laurent et al., 2011; reviewed in Lund et al., 2012 and Nguyen et al., 2012) . Recently, in a large joint study, the International Stem Cell Initiative (ISCI) screened 125 hESC lines worldwide and found this aberration in over 20% of the lines (Amps et al., 2011) . In human induced pluripotent stem cells (hiPSC), the 20q11.21 amplification is found in 18% of the lines (Martins-Taylor et al., 2011) . Furthermore, 20q11.21 gain is also common in human cancers (Scotto et al., 2008; Beroukhim et al., 2010; Tabach et al., 2011) . This suggests that gain of 20q11.21 leads to a phenotype with increased cell survival or proliferative rate, resulting in a selective advantage for mutant cells both in hESC cultures and tumours.
In pluripotent stem cells, genetic instability may not only lead to mutant cells taking over the in vitro culture by selective advantage, but also change their functional characteristics. Genetic changes have been reported to lead to a decrease in differentiation potential linked to an increased capacity to self-renew, and a shift towards malignant properties. Karyotypically abnormal hESC show an increased expression of oncogenes, concurrent with down-regulation of genes related to differentiation (Yang et al., 2008; Werbowetski-Ogilvie et al., 2009) . Gene-expression analysis of hESC with 20q11.21 amplification showed a microarray signature for cancer-associated genes closer to that of an embryonic carcinoma cell line than of an hESC line with normal genetic content. Furthermore, these cells display increased migratory capacity and decreased differentiation potential (Werbowetski-Ogilvie et al., 2009) and intracranial transplantation of neural progenitors derived from these hESC developed into neuroectoderm tumours that displayed a pluripotency signature (Werbowetski-Ogilvie et al., 2012) . These results stress that genetic changes have an adverse impact on the potential use of pluripotent stem cells in cell-based therapy and hamper the integrity and reproducibility of the experimental results.
Despite considerable efforts in the field of cancer genetics to unravel the mechanisms behind gains of 20q11.21, no gene has been conclusively identified as responsible for the selective advantage of this mutation. The amplified region harbours three genes that have been previously suggested as drivers of the selective advantage of this mutation in cancers, namely TPX2, BCL2L1 and ID1. TPX2 plays an essential role in cell cycle progression. It is involved in microtubule organization during mitosis and recruitment of Aurora-A kinase to the spindle apparatus (De Luca et al., 2006; Giubettini et al., 2010) . The role of TPX2 as the driver of gains of 20q11.21 has been studied in several types of cancer (Smith et al., 2006; Tonon et al., 2006) and in the adenoma-to-carcinoma progression (Sillars-Hardebol et al., 2010) . Similarly, the function of the antiapoptotic gene BCL2L1 in cancers has been repeatedly investigated without conclusive results (Smith et al., 2006; Beroukhim et al., 2010; Sillars-Hardebol et al., 2011) . Concerning ID1, its over-expression has been shown to promote cell survival and to induce cell proliferation in several types of cancer cells through the NF-kB pathway (Ling et al., 2003; Kim et al., 2008) , which, in turn can post-transcriptionally modulate BCL2L1 expression (Ling et al., 2003; Meng et al., 2012) . In hESC, at first sight, the most promising candidates appear to be ID1 and BCL2L1. ID1 has been studied as regulator of NANOG (Hong et al., 2011; Romero-Lanman et al., 2012) and BCL2L1 has been previously suggested as the key driver gene because of its crucial role in the control of apoptosis upon loss of cell-to-cell contact (Ohgushi et al., 2010; Amps et al., 2011; Bai et al., 2011) .
In this study, we focused on the characterization of the phenotype of hESC carrying a gain of 20q11.21, and on identifying the gene responsible for the in vitro selective advantage of this mutation. The rationale of our experimental approach was that an increased DNA copy number of 20q11.21 would lead to an increase of the mRNA and subsequently protein levels of the key gene, and this would cause a well-defined phenotype. Knock-down of this gene in mutant cells should restore the wildtype phenotype, and transgenic over-expression in genetically normal cells should mimic the 'mutant' phenotype.
Materials and Methods

Culture of hESC
All VUB hESC lines were derived and characterized as previously described (Mateizel et al., 2006; Geens et al., 2009; Mateizel et al., 2010) . HESC colonies were grown on inactivated mouse embryonic fibroblast (MEF) feeder layers at 378C in 5% CO 2 , using a standard hESC medium: KnockOutTM-DMEM containing 20% KnockOutTM serum replacement (SR, Invitrogen, Carlsbad, USA), 2 mM L-glutamine (Invitrogen), 1% non-essential amino acids (Invitrogen), 0.1 mM b mercapto-ethanol (Sigma-Aldrich, St. Louis, MO), penicillin/ streptomycin 100 U/ml (Invitrogen) and 4 ng/ml human recombinant basic fibroblast growth factor (Invitrogen). HESC colonies were passaged in clumps by mechanical slicing.
For the transduction and transfection experiments, hESC lines were transferred to matrigel TM matrix (BD, Bedford, MA, USA, 1:30 dilution in DMEM-F12, Invitrogen) coated plates using collagenase IV (1 mg/ml in KO-DMEM, Invitrogen). HESC were cultured in mTeSR1 medium (StemCell Technologies, Grenoble, France) until 70% confluency. Enzymatic passaging was performed using dispase (1 mg/ml in DMEM-F12, StemCell Technologies) and clumps of cells were transferred to the new plates.
DNA, RNA extraction and cDNA synthesis
Genomic DNA was extracted twice by phenol and twice by chlorophorm:2-propanol 24:1. The DNA was ethanol precipitated and resuspended in water. Total RNA was extracted using the RNeasy Mini Kit (Qiagen, Solona, Sweden) following the manufacturer's instructions. Reverse transcription was performed using the First-Strand cDNA Synthesis Kit (GE Healthcare, Buckinghamshire, UK) following the manufacturer's protocol.
Total protein extraction
HESC were collected, rinsed three times with ice-cold PBS and lysed with cell lysis buffer (Cytoskeleton, Inc., Denver, CO, USA) supplemented with 1% protease inhibitor cocktail (Sigma-Aldrich), according to the manufacturer's protocol.
Oligonucleotide arrays
Oligonucleotide arrays (Human Genome oligoarray-CGH 44K, Agilent, Santa Clara, CA, USA) were carried out following the manufacturer's instructions with minor modifications as described previously (Buysse et al., 2009) . As reference, genomic DNA extracted from peripheral blood of male or female donors was used. Both test and reference genomic DNA (400 ng each) were labelled with Cy3 or Cy5 (BioPrime Array CGH Genomic Labeling System, Invitrogen) and subsequently purified by precipitation. After 24 h of hybridization at 658C, microarrays were washed and scanned by an Agilent microarray scanner. The scan images were processed with Feature Extraction Software 10.1 (Agilent) and further analysed and visualized using the arrayCGHbase software (http://medgen.ugent.be/arraycghbase/).
Reverse transcription polymerase chain reaction
RT-PCR for BCL2L1 was performed to check the expression and the ratio of two different isoforms, Bcl-xL and Bcl-xS, at an mRNA level. PCR reactions were performed in 25 ml total volume, comprising 12.5 ml 2× GoTaq-Green master mix (Promega, Madison, WI, USA) with 900 nM of one of the following primers: BCL2L1 (forward, 5 ′ -GGC ATT CAG TGA CCT GAC ATC-3 ′ ; reverse, 5 ′ -AGT CAT GCC CGT CAG GAA C-3 ′ ) or Ubiquitin C (UBC, forward, 5 ′ -CGC AGC CGG GAT TTG-3 ′ ; reverse, 5 ′ -TCA AGT GAC GAT CAC AGC GA-3 ′ ) and 50 ng of cDNA using the following cycling parameters: 1 min at 948C, 30 cycles of 30 s at 948C, 30 s at 588C and 30 s at 728C. Agarose gel electrophoresis was performed with 1 ml of the molecular weight marker VIII (Roche Diagnostics GmbH, Mannheim, Germany) and 5 ml of each PCR product and DNA fragments were visualized using Proxima C16 phi (ISOGEN, Life science).
Quantitative real-time polymerase chain reaction (qRT-PCR)
Quantitative RT -PCR was carried out on an ABI 7500 real-time thermocycler (Life Technologies, Foster city, CA, USA). Reactions were performed under standard conditions, in 25 ml total volume, comprising 12.5 ml 2× qPCR MasterMix Plus Low ROX with UNG (Eurogentec), 50 ng of cDNA, 1.25 ml of one of the TaqMan gene expression assays for DEFB119, REM1, NCRNA00028, HM13, ID1, miR-3193, COX4I2, BCL2L1 isoform 1, BCL2L1 isoform 2, TPX2, POFUT1 isoform 1, POFUT1 isoform 2, Pri-miR-1825, miR-1825, KIF3B as listed in Supplementary data, Table SI or 900 nM primer mix and 250 nM probes for NANOG, PSiMCT-1 or the housekeeping gene UBC as listed in the Supplementary data, Table SII .
Normalization against the endogenous control UBC using the DDCt method of quantification was applied to relatively quantify gene expression between multiple samples and the relative amount of mRNA was calculated as 2 2DDCt .
In the gene expression studies using multiple endogenous controls (UBC, GAPDH and GUSB), the real-time PCR was carried out using the ViiA 7 thermocycler (Life Technologies) and analysed using the ViiA 7 software version 1.2 (Life Technologies). Reactions were performed under the fast mode, in Gain of 20q11.21 in human embryonic stem cells 20 ml total volume, comprising 10 ml 2× TaqMan Fast Universal Master Mix (Life Technology), 40 ng of cDNA, 1 ml of TaqMan gene expression assays for HM13, ID1, BCL2L1 isoform 1, BCL2L1 isoform 2, TPX2, POFUT1 isoform 1, KIF3B and GUSB (as shown in Supplementary data, Table SI) or 900 nM primer mix and 250 nM probes for UBC and GAPDH (see Supplementary data, Table SII) .
For mature miRNA quantification, a two-step protocol was applied on 10 ng of total RNA for each sample including reverse transcription with an miRNA-specific primer and TaqMan MicroRNA Reverse Transcription Kit (Life Technologies), followed by qRT -PCR with TaqMan gene expression assays. Normalization was carried out against miR-26a.
We analysed at least five biological replicates for mutant and wild-type lines, the details on the lines and passages can be found in the Supplementary data, Figs S2 and S4.
Determination of gene copy number using qRT -PCR
Copy number quantification was performed on an ABI 7500 real-time thermocycler (Life Technologies) according to the manufacturer of the copynumber assays (Life Technologies). The used assays were copy number reference assay for RNAseP (4403328), ID1 (Hs01892845_cn), POFUT1 (Hs02487189_cn), ASXL1 (Hs01059149_cn) and DNMT3B (forward, 5
′ -AGT CCT TGG GTG AAT TTG CAA-3 ′ ; reverse, 5 ′ -CAA TTC CCC TAA TTC AGC ATC CT-3 ′ ; probe, 6-FAM-TGT TGC CCT AGG ATG TTA CAT GCT GAG CTG-MGB).
Western blot
Twenty micrograms of total protein extracts was electrophoresed by SDS-PAGE in 10 -12% polyacrylamide gels. Proteins were blotted onto nitrocellulose membrane (Sigma-Aldrich) by semidry blotting. Membranes were blocked with 5% non-fat dried milk in Tris-buffered saline containing 0.1% Tween 20 and then incubated with primary antibody against Bcl-xL/S (Cat. 556361, BD Bioscience, San Jose, CA, USA) or Beta-actin (ab3280, Abcam, Cambridge, UK) as loading control. Secondary horseradish peroxidase-conjugated antibody was applied at a 1:5,000 dilution, followed by the ECL plus Western blotting system (Amersham, Piscataway, NJ, USA) for visualization.
Sandwich ELISA
Sandwich ELISAs were conducted using the human total Bcl-xL ELISA kit for Bcl-xL (DuoSet w IC, R&D Systems, Inc., Minneapolis, USA), human DNAbinding protein inhibitor ID-1 (ID1) ELISA kit (Cusabio Biotech Co., Ltd., Hubei, China), and G-LISA 
Apoptosis in hESC colonies by TUNEL staining
The TUNEL staining was performed using In Situ Cell Death Detection Kit, TMR red (Roche applied science) on fixed hESC colonies following the manufacturer's protocol. Briefly, pairs of wild-type and mutant hESC lines were cultured in four-well plates for 4 days in normal culture conditions. After fixation and permeabilization, TUNEL reaction mixture (5 ml of Enzyme solution: 45 ml of Label Solution) was added to the wells and incubated for 1 h, at 378C in the dark. Cells treated with 50 U/ml DNaseI (Qiagen) for 10 min before staining were used as a positive control, while in the negative control only the Label Solution was added. Cells were washed three times with PBS, mounted with DAPI and evaluated using an IX-81 fluorescence microscope (Olympus, Aartselaar, Belgium).
Apoptosis in single-cell suspension by Annexin V: PI staining
Single hESC were collected using non-enzymatic cell dissociation solution (C5914, Sigma-Andrich). The cell suspension was passed through a 40 mm cell strainer to remove remaining clumps and pelleted by centrifugation at 115 × g, 5 min. The pellet was resuspended and diluted to 5 × 10 6 -5 × 10 7 cells/ml in the hESC medium. Hundred ml of cell suspension was Annexin V-PI stained following the manufacturer's protocol (Tali Apoptosis Kit (A10788)-Annexin VAlexa Fluor 488 and propidium iodide; Invitrogen) and analysed by Tali image-based cytometer (Invitrogen). For the green fluorescence protein (GFP) positive transduced hESC, Annexin V Alexa Fluor 555 (A35108, Invitrogen) was used.
Clonogenic efficiency assay
Single cell suspensions were prepared as described before. Ten thousand cells were plated on MEF-coated culture dishes with 60 mm diameter. The experiments were performed in triplicate for each hESC line. The clonogenic efficiency was determined by averaging the number of colonies from triplicate after 10 days of culture.
Immunocytochemistry for NF-kB p65
HESC were cultured in four-well plates for 24 h, fixed with 4% formalin, permeabilized using PBS containing 0.25% Triton X-100 for 10 min and then blocked in 2% normal goat serum, 2% BSA and 0.3% Triton-X for 1 h. The anti-NF-kB p65 antibody (ab31481, Abcam) applied for 2 h at 1/200 dilution. The Alexa Fluor 488 conjugated goat anti-rabbit secondary antibody, diluted 1/500, was applied for 1 h. Finally, hESCs were mounted with Prolong Gold Antifade reagent containing DAPI (Invitrogen) and evaluated using an IX-81 fluorescence microscope (Olympus).
Knock-down of BCL2L1 in hESC carrying a 20q11.21 gain
The BLOCK-iT Fluorescent Oligo (Invitrogen) was used as a positive control for the transfection of hESC and to optimize the transfection conditions. We established that the use of 25 nM of siRNA and 0. 
Transgenic over-expression of Bcl-xL in genetically normal hESC lines by lentiviral transduction
The human Bcl-xL gene was cloned into a lentiviral vector pCDH (LV500A-1) purchased from System Biosciences (Mountain View, CA, USA). Bcl-xL expression was driven by the elongation factor-1alpha (EF-1alpha) promoter, whereas the expression of GFP and puromycin resistance gene was under the control of the phosphoglycerate kinase I gene promoter (PGK). The packaging plasmid pCMVDR8.9 and VSV.G encoding plasmid pMD.G were a gift from Dr D. Trono (University of Geneva). Lentiviral particles were generated by transient co-transfection of human embryonic kidney 293T cells as described before (Goyvaerts et al., 2012) . The viral particles were 300-fold concentrated by ultracentrifugation, suspended in PBS containing 10 mg/ml protamine sulphate (LeoPharma) and kept at 2808C. Virus titres were determined by measuring the reverse transcriptase activity as previously described (Breckpot et al., 2010) .
A genetically normal subline of VUB03 was cultured on matrigel-coated dishes 24 h prior to the transduction. The cells were transduced twice, first with 10 ml of 1 × 10 6 TU/ml viral particles, and 6 -8 h later 30 ml of 1 × 10 6 TU/ml viral particles. GFP-positive cells were visualized using an IX-81 fluorescent microscope (Olympus) and selected by continuously adding 1 mg/ml of puromycin (Sigma-Aldrich) to the culture medium. After two passages during which the puromycin-containing medium was daily refreshed, .80% of the cells were GFP positive.
Statistical analysis
The data were subjected to statistical analysis using two-tailed Student's t-test. The results with the values of P ≤ 0.05 were considered statistically significant.
Results
The common region of 20q11.21 gain in the VUB hESC lines spans 1 Mb
In our laboratory, we previously found an increased copy number of 20q11.21 in four hESC lines, VUB01, VUB02, VUB03 and VUB07 (Spits et al., 2008) . The breakpoints of the mutation were further narrowed down using oligonucleotide arrays. Copy-number analysis by qRT -PCR for the genes ID1, POFUT1, ASXL1 and DNMT3B was used to validate these results and showed that mutant sub-lines of VUB03 and VUB02 carry three and four copies of 20q11.21, respectively. For VUB01, the results showed that there are two different mutant sub-lines, with either three or four copies of the region (Supplementary data, Fig. S1 ). All four lines share the same proximal breakpoint, upstream of the DEFB116 gene, while the distal breakpoints are different for each line. The minimal amplicon in our lines spans 1 Mb (from positions 29.888-30.914 Mb on GRCh37), encompassed 26 known genes and 2 microRNAs, from the DEFB116 to KIF3B genes (Fig. 1) . Our minimal amplicon has a size similar to the minimal amplicon reported by Laurent et al. (2011) and is slightly larger than the minimal amplicon described in the recent ISCI study (Amps et al., 2011) . VUB07 was further excluded from this study because it also carried an amplification of the SOX2 gene (Spits et al., 2008) . The experiments were performed on pairs of sub-lines of the VUB01, VUB02 and VUB03 with and without the mutation. Four other hESC lines (VUB04, VUB09, VUB14, VUB26) whose 20q11.21 copy number was tested by qRT -PCR and showed no gain of this region were included as negative controls in several of the experiments.
Mutant hESC have increased mRNA levels of HM13, BCL2L1, ID1, KIF3B and the immature form of miR-1825
Given that the expected increase in mRNA levels in mutant cells is 1.5-to 2-fold (mutant cells have either three or four copies of the duplicated genes instead of two), we studied the gene expression of all the genes on the minimal amplicon by qRT -PCR, which is sensitive to small gene-expression changes. We studied all loci unique to that region that showed histone marks consistent with enhanced promotor activity in hESC (Chip-seq data available at UCSC genome browser, http:// genome.ucsc.edu/), and included the microRNAs miR-1825 (in mature and immature form, Pri-miR-1825) and miR-3193, the non-coding RNA NCRNA00028 and pseudogene PSiMCT-1. DEFB119, REM1, COX4I2 and NCRNA00028 had closed histone marks and were included as a control. We found that DEFB119, REM1, COX4I2, POFUT1 isoform 2, miR-3193 and NCRNA00028 are not expressed or expressed at very low levels in hESC. Pooled qRT -PCR data of three mutant and three wild-type lines (two biological replicates per line and three technical replicates per sample) show that the mRNA levels of TPX2, POFUT1 isoform 1, miR-1825 and PSiMCT-1 are not increased in the mutant sub-lines. HM13, ID1, BCL2L1 isoform 1 (Bcl-xL), BCL2L1 isoform 2 (Bcl-xS), 
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Pri-miR-1825 and KIF3B are .2-fold up-regulated in the mutant lines. Among these, only HM13, BCL2L1 isoform 1, BCL2L1 isoform 2 and Pri-miR-1825 show a statistically significant increase (P , 0.05) (Fig. 2a  and Supplementary data, Fig. S2 ).
Based on these data, we further focused on two most promising genes in the region: ID1 and BCL2L1. Both genes are up-regulated in the mutant cells, and, despite that the fold-change was not statistically significant for ID1, its known functions made it a very appealing candidate. Overexpression of ID1 has been shown to promote cell survival by activation of the NF-kB pathway (Ling et al., 2003; Kim et al., 2008) , which, in turn has been shown to up-regulate Bcl-xL (Ling et al., 2003; Meng et al., 2012) , and plays a role in the regulation of NANOG in embryonic stem cells (Hong et al., 2011; Romero-Lanman et al., 2012) .
We did not further evaluate the role of the Pri-miR-1825 in mutant cells because the mature form of the microRNA (miR-1825) did not show an increased expression. HM13 (minor histocompatibility antigen 13), which encodes a poorly studied protein that localizes to the endoplasmic reticulum and is involved in catalysing intramembrane proteolysis of some signal peptides, was excluded from further study because it has no known function in hESC (Gene ID: 81502, www. ncbi.nlm.nih.gov).
ID1 does not play a key role in the selective advantage of hESC carrying a 20q11.21 gain First, we quantified the levels of ID1 protein in mutant and wild-type cells (Fig. 2b) and carried out immunostaining for NF-kB p65 (Supplementary data, Fig. S3 ). We found no increase of the ID1 protein levels and no evidence of an increased activation of the NF-kB pathway in the mutant cells. Furthermore, we quantified the mRNA levels of NANOG, POU5F1, and SOX2 in mutant and wild-type hESC (Fig. 2c , Supplementary data, Fig. S4 ). In line with the results of the protein quantification and immunostaining, there was no increase of NANOG mRNA. Furthermore, the mRNA gene expression levels of SOX2 and POU5F1 were also not statistically significant different between mutant and wild-type hESC, suggesting that, 20q11.21 gain in hESC does not affect the self-renewal of the mutant hESC lines. These results suggest that ID1 does not play a key role in the selective advantage of gains of 20q11.21 in hESC.
Bcl-xL is over-expressed in hESC carrying a 20q11.21 gain and promotes cell survival upon loss of cell-to-cell contact BCL2L1 can produce two isoforms by alternative splicing: an antiapoptotic isoform, Bcl-xL, and a pro-apoptotic isoform, Bcl-xS. We investigated the ratio between the two isoforms (Bcl-xL and Bcl-xS) by reverse transcription-PCR (RT-PCR) and by qRT-PCR. The results showed that the anti-apoptotic isoform Bcl-xL had a 30-fold higher expression when compared with the pro-apoptotic isoform, Bcl-xS, both in mutant and wild-type cells (Fig. 2d) . Furthermore, western blot analysis showed that the short isoform Bcl-xS was not detectable at the protein level (Fig. 2e) . We then compared the expression of Bcl-xL protein in mutant and wild-type cells by sandwich ELISA. The results showed on average a 3-fold over-expression of Bcl-xL in mutant compared with wild-type hESC (P , 0.05) (Fig. 2f) .
The RhoA/ROCK pathway is strongly induced upon disruption of cell-to-cell contact in hESC, and is responsible for their poor survival in a dissociated state. Loss of cell-to-cell contact induces activation of RhoA by phosphorylation, which starts the cascade leading to apoptosis through the mitochondrial pathway. In turn, Bcl-xL antagonizes the signals mediating the mitochondrial apoptosis pathway, downstream of RhoA activation (Ohgushi et al., 2010; Bai et al., 2011) .
We investigated if mutant and wild-type cells showed different levels of activated RhoA upon colony dissociation. We carried out sandwich ELISA for the active form of RhoA on hESC collected using collagenase (which minimally disrupts cell-to-cell contact) and a single-cell dissociation buffer. The results showed 1.8-fold increase of active RhoA in the single-cell dissociated hESC when compared with the hESC in colonies (P , 0.001), but no differences were found between mutant and wild-type cells after both collagenase (P ¼ 0.81) and single-cell (P ¼ 0.81) collection methods (Fig. 2g) .
We evaluated the levels of apoptosis in mutant and wild-type hESC by two different approaches. First, we carried out TUNEL staining on formaldehyde fixed hESC colonies 4 days after passaging. We found that the percentage of apoptotic cells is specific to each hESC line. VUB03 showed on average 10% of apoptotic cells, while VUB01 and VUB02 had 5%. The results also showed fewer apoptotic cells in the mutant relative to the wild-type sub-lines, albeit the difference was small Figure 2 Gene expression and protein levels of mutant and wild-type hESC lines. In all panels, mt stands for mutant (i.e. carrying the 20q11.21 duplication) and wt stands for wild-type (cells without the 20q11.21 duplication). (a) The average fold-change of mRNA levels of all loci studied of the common region of duplication as measured by qRT -PCR in mutant hESC when compared with wild-type. Genes with an X did not show expression or the expression was very low. The error bars represent the standard deviation to the average fold-change in gene expression. At least five biological replicates for mutant and wild-type lines were analysed. The data for all biological replicates can be found in the Supplementary data, Fig. S2 . Statistically significant differences are indicated with an asterisk (*). (b) Levels of ID1 protein in wild-type and mutant cells, measured by ELISA. All samples were analysed in triplicate. There were no statistically significant differences between mutant and wild-type cells. (c) Fold-change of mRNA levels in mutant hESC when compared with their wild-type counterparts for NANOG, POU5F1 and SOX2 measured by qRT-PCR. At least five biological replicates for mutant and wild -type lines were analysed. The error bars represent the standard deviation to the average fold-change in gene expression. The data for all biological replicates can be found in the Supplementary data, Fig. S4 . There were no statistically significant differences between mutant and wild-type cells. (d) RT-PCR showing the ratio between the mRNA levels for both isoforms of BCL2L1. HF is a sample from human fibroblasts and MWM stands for molecular weight marker. UBC (Ubiquitin C) was used as an endogenous control. (e) The western blot result for Bcl-xL/S showed no expression of anti-apoptotic isoform Bcl-xS at the protein level. (f) Total Bcl-xL protein in mutant and wild-type hESC lines, measured by ELISA. All samples were analysed in triplicate. The difference between the pooled data of mutant and wild-type lines is statistically different. (g) Levels of activated RhoA in wild-type and mutant hESC in whole colonies (collagenase collected, minimizing loss of cell-to-cell contact) and in single-cell suspension (complete loss of cell contacts), measured by ELISA. All samples were analysed in triplicate. There were no statistically significant differences between mutant and wild-type cells, but between hESC collected as whole colonies or as single cells.
(first time point in Fig. 3a and b) . Secondly, we performed a time-course analysis of apoptosis on dissociated hESC colonies ( Fig. 3a and b) . We used an Annexin V-PI staining on the hESC that were kept for 1, 3, 5 and 7 h as single cells in suspension. The results indicated that the hESC lines carrying the 20q11.21 gain underwent significantly fewer apoptosis when compared with the wild-type counterparts. After 1 h the percentages of apoptosis were similar between wild-type and mutant sub-lines. However, the wild-type sub-lines showed a strong increase in the proportion of apoptotic cells after 3 h, while the mutant sub-lines showed approximately half of these levels.
Finally, we evaluated the clonogenic capacity of the mutant and wild type. We plated 10 000 single cells to the 60 mm culture dishes coated with a mouse embryonic fibroblasts feeder layer and performed the experiments in triplicate. The number of the colonies in each plate was counted after 10 days and the clonogenic efficiency was determined by averaging the number of colonies obtained in three experiments. The results showed that mutant hESC had approximately two times higher clonogenic efficiency when compared with the wild-type counterparts (P , 0.05) (Fig. 3c) .
Knock-down of BCL2L1 in hESC carrying 20q11.21 gains restores the wild-type phenotype
To confirm the anti-apoptotic effect of Bcl-xL in the hESC carrying 20q11.21 gains, we knocked-down BCL2L1 in two mutant hESC lines and investigated whether decreased BCL2L1 expression restores the wild-type phenotype. BCL2L1 knock-down and control knock-down mutant hESC were created by transfection using Lipofectamin 2000 with BCL2L1 siRNA and siControl, respectively. Transfected hESC were collected and further characterized 72 h post-transfection. In the BCL2L1 knock-down mutant VUB03, almost no mRNA of BCL2L1 was detected, while the BCL2L1 knock-down mutant VUB02 displayed an 2-fold decrease in the mRNA expression level of BCL2L1 (Fig. 4a ). The protein quantification by ELISA showed a decrease in the Bcl-xL protein levels in both BCL2L1 knock-down lines. The decrease was not as drastic as for the mRNA levels, suggesting a relatively long half-life of the protein (Fig. 4b) . Nevertheless, the time-course experiments for the induction of apoptosis showed that the mutant cells with BCL2L1 knock-down were significantly more sensitive to the loss of cell-to-cell contact than the control cells ( Fig. 4c and d) .
Transgenic over-expression of Bcl-xL in genetically normal hESC mimics the phenotype caused by the gain of 20q11.21
We next investigated if ectopic over-expression of Bcl-xL can inhibit the dissociation-induced apoptosis in hESC. Bcl-xL-over-expressing hESC (VUB03-Bcl-xL) and control hESC (VUB03-GFP) were established by lentiviral transduction followed by several rounds of selection using puromycin. Compared with the VUB03-GFP control, Bcl-xL expression in VUB03-Bcl-xL was .250-fold increased at mRNA (Fig. 4e) and 5.7-fold at the protein level (Fig. 4f) . Accordingly, the proportion of Annexin V-positive cells was 20% lower in VUB03-Bcl-xL when compared with the control line VUB03-GFP at each time point of the experiment (Fig. 4g) .
Discussion
20q11.21 amplification is a recurrent mutation that has been repeatedly reported in hPSC as well as many types of human cancer, suggesting that this mutation confers a selective advantage to these cells. In this study, we first established the minimal region of 20q11.21 gain in our hESC lines, characterized the phenotypes of mutant and wild-type hESC in order to establish the selective advantage of the mutant sub-lines and identified the key driver gene of phenotype as BCL2L1.
The minimal amplicon in our study is of 1 Mb and contains a discrete number of loci, including 26 known genes, two micro-RNAs and one non-coding RNA. Gene copy number of several loci within the smallest region of amplification confirmed the presence of three to four copies in the lines under investigation. We carried out qRT -PCR for all known genes, excluding those loci whose histone marks suggested no expression in hESC (for instance the DEFB cluster of genes) or those that were not unique to the common region of gain, but are found in other genomic regions as well. We found that only HM13, ID1, both isoforms of BCL2L1, Pri-miR-1825 and KIF3B showed the expected minimal 1.5-fold increase in mRNA levels in the mutant cells. However, this increase was only statistically significant for HM13, both isoforms of BCL2L1 and Pri-miR-1825. It is noteworthy that fold-changes between 1.5 and 2 are on the technical limit of qRT-PCR, in which each PCR Gain of 20q11.21 in human embryonic stem cells cycle indicates a doubling of the quantity of template. In this study, we used multiple endogenous controls and numerous replicates to minimize experimental variation.
Based on the qRT-PCR results and the known functions of genes in the minimal amplicon, we narrowed down the potential genes involved in the selective advantage of the 20q11.21 mutation in hESC. The most promising candidates were ID1 and BCL2L1, because of previously published studies involving them in stem cell biology, including a potential link between them two. ID1 has been studied as regulator of NANOG (key player of the 'stemness' pathway) and an inhibitor of differentiation in different stem cell types, including hESC (Hong et al., 2011; Romero-Lanman et al., 2012) . It has been reported in the field of cancer research that the over-expression of ID1 increases cell viability and makes the cells more resistant to apoptosis Meng et al., 2012) . The large isoform of BCL2L1 (Bcl-xL) is an inhibitor of the mitochondrial apoptosis pathway, and has been shown to play a key role in hESC survival upon loss of cell-to-cell contact (Ohgushi et al., 2010; Bai et al., 2011) . Furthermore, it has been suggested that ID1 is able to induce Bcl-xL. Meng et al. (2012) showed that Bcl-xL expression was two times increased in thyroid cancer cells over-expressing ID1, and that this was a result of the activation of the NF-kB pathway. Conversely, Kim et al. (2008) found that ID1 over-expression resulted in the up-regulation of Bcl-2 and down-regulation of Bax, whilst Bcl-xL expression remained unchanged.
Protein quantification of ID1 revealed no differences between mutant and wild-type cells, and we found no evidence of activation of the NF-kB pathway. This, along with the lack of increase of NANOG mRNA, in the mutant cells suggests that ID1 does not play a role in the selective advantage of 20q11.21 mutations in hESC.
On the other hand, hESC carrying the 20q11.21 gain showed increased Bcl-xL mRNA and protein levels. We found that these sublines have significantly lower levels of apoptosis upon loss of cell-to-cell contact and increased clonogenic efficiency, leading to an increased cell-survival during culture passaging. This is consistent with the work of Ohgushi et al. (2010) who investigated the role of Bcl-xL in dissociation-induced apoptosis and found that hESC over-expressing Bcl-xL displayed lower levels of apoptosis upon loss of cell-to-cell contact. Bai et al. (2011) also observed that hESC over-expressing Bcl-xL showed lower levels of apoptosis and increased clonogenic capacity. In cancer research, cell lines carrying a 20q11.21 amplification show a strong dependence on BCL2L1 expression. Cancer lines with 20q11.21 gain show a stronger reduction of proliferation and increase in apoptosis when subjected to BCL2L1 knock-down than lines without the mutation (Beroukhim et al., 2010) . Also, 20q11.21 gain has been associated with the acquisition of resistance to the DNAdamaging drug cisplatin. The authors reasoned that over-expression of anti-apoptotic gene, Bcl-xL offered the mutant cells survival advantage and made them more resist to the apoptosis signal (Rao et al., 1998) .
In our hands, transgenic over-expression of BCL2L1 in genetically normal hESC also lead to decreased apoptosis upon loss of cell-to-cell contact and knock-down of this gene in mutant hESC restored the wildtype phenotype. Nevertheless, the effect of the transgenic manipulations was less pronounced than the naturally occurring mutation. In the case of the knock-down experiments, this is explainable by the fact that not all cells undergo transfection, and that the Bcl-xL protein proved to have a relatively long half-life ( Fig. 4a and b) . Another factor to take into account when making the comparisons is that the apoptosis curves are different for hESC cultured on mouse feeder cells and Matrigel matrix.
HESC cultured on feeder cells show a dramatic increase in apoptotic cells between 1 and 3 h after dissociation and this number stays similar after that point ( Fig. 3a and b) . For hESC cultured on Matrigel, the increase in apoptotic cells is gradual and continuous ( Fig. 4c and d) . The differences are most likely due to the nature of culture conditions and how it influences the cell-to-cell contact of the hESC.
In summary, our results show that hESC with a gain of 20q11.21 have on average a 2.3-fold increase of Bcl-xL mRNA levels and a 3-fold increase in the protein levels. Consistently, the mutant hESC undergo 2-to 3-fold less apoptosis after dissociation, and are approximately a 2-fold more efficient in forming colonies from a single cell when compared with wild type. The role of Bcl-xL in the phenotype of hESC carrying 20q11.21 gain was further confirmed by transgenic over-expression of Bcl-xL in wild-type cells and BCL2L1 knock-down in mutant hESC. The resistance to apoptosis-inducing stimuli supposes a selective advantage for the mutant cells, explaining the high frequency of this mutation in hPSC and probably cancer cells. Taken all together, our data strongly suggest that BCL2L1 is the key driver gene of the 20q11.21 gains in hESC.
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